Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Diagnostic Substances
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 830
IPSCIO Record ID: 27645
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5
4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas
5,286,647 – human-human hybridomas for neoplasms
5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.
5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.
6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions
6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
6,051,693 – CLNH11-specific antibodies
6,090,924 – human-human CLNH5-specific antibodies
6,165,467 – stabilized human monoclonal antibody preparation
The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company
IPSCIO Record ID: 5297
The term 'PSMP' shall mean prostate specific membrane peptides which shall include any peptide sequence appearing within the PSMA protein.
The term 'Licensed Products' shall mean products for the immunotherapy of prostate cancer which are produced by [ *** ], with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP.
The term 'Licensed Processes' shall mean any process for the immunotherapy of prostate cancer in patients by [ *** ] including, but not limited to [ *** ], ex vivo, with a composition including PSMA and/or PSMP, and/or the mimetopes of PSMA or PSMP, and [ *** ] the use or practice of which would, but for the licenses granted herein, infringe one or more Valid Claims of an issued patent or pending patent application included in SKICR Patent Rights.